Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Docusign's contract management software allowed businesses to continue making deals during the worst of the COVID-19 pandemic. Demand faded when social conditions returned to normal after 2022, which sent Docusign stock plunging.
The gigantic push towards Artificial Intelligence to turbocharge computer functions and other tasks will greatly benefit society.
DOCU beats Q4 estimates with solid earnings and revenue growth, while subscription gains and upbeat fiscal 2027 guidance highlight steady momentum.
Docusign delivered Q4 results exceeding expectations, with strong ARR and robust free cash flow growth outpacing revenue gains. Subscription revenue, representing 98% of DOCU's total, grew 8% Y/Y with stable 83.4% gross margins, underscoring business resilience. Free cash flow surged 25% Y/Y to $350M, with margins expanding 6 points to 42%, highlighting operational efficiency.
Docusign, Inc. (DOCU) Q4 2026 Earnings Call Transcript
The headline numbers for DocuSign (DOCU) give insight into how the company performed in the quarter ended January 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
DocuSign (DOCU) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.86 per share a year ago.
DocuSign stock price has pulled back in the past few months, and is hovering at its lowest level since December 2023. DOCU was trading at $47 on Friday, down by 56% frm its highest point in December 2024.
Bridgefront Capital LLC purchased a new stake in shares of Docusign Inc. (NASDAQ: DOCU) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 11,267 shares of the company's stock, valued at approximately $812,000. A number of other institutional investors and hedge funds
Glenmede Investment Management LP lowered its position in Docusign Inc. (NASDAQ: DOCU) by 3.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 719,742 shares of the company's stock after selling 24,886 shares during the period. Glenmede Investment Management LP owned